Clinical and Pathological Characteristics of Autoimmune Hepatitis with Acute Presentation

Yi Shen, Changli Lu, Ruoting Men, Jianping Liu, Tinghong Ye, Li Yang, Yi Shen, Changli Lu, Ruoting Men, Jianping Liu, Tinghong Ye, Li Yang

Abstract

Aim. To study the differences between acute presentation-autoimmune hepatitis (A-AIH) and chronic autoimmune hepatitis (C-AIH). Methods. Through long-term follow-up, 80 patients were included in our study by using the revised international autoimmune hepatitis group (IAIHG) score and were divided into acute and chronic groups for comparison. Results. No significant difference was found in the gender, age, IAIHG score (pretreatment/posttreatment), definite diagnosis rate, extrahepatic autoimmune disease, onset time, or treatment before biopsy between the acute and chronic groups. In terms of clinical symptoms, A-AIH patients were more prone to jaundice, anorexia, yellow urine, and detesting oil than C-AIH patients, but melena only occurred in chronic group (P < 0.05). The acute group exhibited more severe injury upon histological evaluation, with lobular inflammation and bile duct injury, especially central necrosis of the lobule, more pronounced in this group (P < 0.05). Conclusion. A-AIH had manifestations of acute hepatitis and presented cholestasis. Serum indicators could preliminarily distinguish A-AIH and C-AIH. Histologically, the primary manifestation of A-AIH was lobular inflammation, which was usually accompanied by lobular central necrosis. For the diagnosis of A-AIH, more attention should be paid to long-term follow-up. This study was registered at ClinicalTrials.gov (identifier: NCT02994537).

Figures

Figure 1
Figure 1
Flow chart. The figure shows the entire process and the contents of the study. IAIHG: international autoimmune hepatitis group; AIH: autoimmune hepatitis; A-AIH: acute presentation-autoimmune hepatitis; TB: total bilirubin; ALT: alanine aminotransferase; AST: aspartate transaminase; C-AIH: chronic autoimmune hepatitis; HGB: haemoglobin; PLT: platelet; WBC: white blood cell; DB: direct bilirubin; ALB: albumin; GLB: globulin; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; PT: prothrombin time; INR: international normalized ratio; IgG: immunoglobulin G; ANA: anti-nuclear antibody; AMA: anti-mitochondrial antibody; LKM: liver kidney microsomal; LC: liver cytosol; SLA: soluble liver antigen; ANCA: anti-neutrophil cytoplasmic antibody; Coombs: Coombs test; G: inflammation grade; S: fibrosis stage.
Figure 2
Figure 2
Histological features of A-AIH and C-AIH. A-AIH (A1–4) and C-AIH (C1–4): A1, C1: A1 shows multiacinar and centrilobular necrosis in A-AIH, which is uncommon in C-AIH (H&E, ×200, small pictures emphasized the typical areas in the big pictures); A2, C2: the main manifestation of A-AIH is cellular swelling, ballooning change, and lobular inflammation accompanied by mild interface inflammation; however, C-AIH often has moderate-to-severe interface inflammation caused by lymphoplasmacytic infiltration (H&E ×200); A3, C3: CK7 staining showing regeneration of cholangiocytes due to the multiacinar necrosis of hepatocyte in A-AIH. However, bile duct regeneration was less likely to be found in C-AIH (CK7, ×200); A4, C4: blue staining shows fibrosis in the portal area; fibrous septa were found in the chronic group but not the acute group (Masson trichrome staining, ×200).
Figure 3
Figure 3
ROC curve of ALB. The area under the receiver operating characteristic (ROC) curve was 0.765 for ALB, 95% confidence interval (CI) was 0.662–0.869, and rates for sensitivity and specificity were 72.9% and 68.7%, respectively.

References

    1. Manns M. P., Lohse A. W., Vergani D. Autoimmune hepatitis. Journal of Hepatology. 2015;62(1, supplement):S100–S111. doi: 10.1016/j.jhep.2015.03.005.
    1. Krawitt E. L. Autoimmune hepatitis. The New England Journal of Medicine. 2006;354(1):54–66. doi: 10.1056/nejmra050408.
    1. Czaja A. J., Carpenter H. A. Sensitivity, specificity, and predictability of biopsy interpretations in chronic hepatitis. Gastroenterology. 1993;105(6):1824–1832. doi: 10.1016/0016-5085(93)91081-R.
    1. Kessler W. R., Cummings O. W., Eckert G., Chalasani N., Lumeng L., Kwo P. Y. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clinical Gastroenterology and Hepatology. 2004;2(7):625–631. doi: 10.1016/S1542-3565(04)00246-0.
    1. Hofer H., Oesterreicher C., Wrba F., Ferenci P., Penner E. Centrilobular necrosis in autoimmune hepatitis: A histological feature associated with acute clinical presentation. Journal of Clinical Pathology. 2006;59(3):246–249. doi: 10.1136/jcp.2005.029348.
    1. Onji M. Proposal of autoimmune hepatitis presenting with acute hepatitis, severe hepatitis and acute liver failure. Hepatology Research. 2011;41(6):497–497. doi: 10.1111/j.1872-034X.2011.00810.x.
    1. Ferrell L. D., Kakar S. Liver Pathology. Vol. 517. New York, NY, USA: Demos Medical Publishing; 2011.
    1. Chinese Medical Association. Consensus on the diagnosis and treatment of autoimmune hepatitis. Journal of Hepatobiliary Disease. 2016;01:9–22.
    1. Abe M., Hiasa Y., Masumoto T., et al. Clinical characteristics of autoimmune hepatitis with histological features of acute hepatitis. Hepatology Research. 2001;21(3):213–219. doi: 10.1016/S1386-6346(01)00109-7.
    1. Miyake Y., Iwasaki Y., Kobashi H., et al. Autoimmune hepatitis with acute presentation in Japan. Digestive and Liver Disease. 2010;42(1):51–54. doi: 10.1016/j.dld.2009.04.009.
    1. Takahashi H., Zeniya M. Acute presentation of autoimmune hepatitis: Does it exist? A published work review. Hepatology Research. 2011;41(6):498–504. doi: 10.1111/j.1872-034X.2011.00808.x.
    1. Fujiwara K., Nakano M., Yasui S., Okitsu K., Yonemitsu Y., Yokosuka O. Advanced histology and impaired liver regeneration are associated with disease severity in acute-onset autoimmune hepatitis. Histopathology. 2011;58(5):693–704. doi: 10.1111/j.1365-2559.2011.03790.x.
    1. Kogan J., Safadi R., Ashur Y., Shouval D., Ilan Y. Prognosis of symptomatic versus asymptomatic autoimmune hepatitis: A study of 68 patients. Journal of Clinical Gastroenterology. 2002;35(1):75–81. doi: 10.1097/00004836-200207000-00016.
    1. Manns M. P., Czaja A. J., Gorham J. D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51(6):2193–2213. doi: 10.1002/hep.23584.
    1. Yeoman A. D., Westbrook R. H., Al-Chalabi T., et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology. 2009;50(2):538–545. doi: 10.1002/hep.23042.
    1. Alvarez F., Berg P. A., Bianchi F. B., et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology. 1999;31(5):929–938. doi: 10.1016/s0168-8278(99)80297-9.
    1. Miyake Y., Iwasaki Y., Terada R., et al. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. Journal of Hepatology. 2005;43(6):951–957. doi: 10.1016/j.jhep.2005.06.006.
    1. Scheuer P. J., Standish R. A., Dhillon A. P. Scoring of chronic hepatitis. Clinics in Liver Disease. 2002;6(2):335–347. doi: 10.1016/S1089-3261(02)00009-0.
    1. Iwai M., Jo M., Ishii M., Mori T., Harada Y. Comparison of clinical features and liver histology in acute and chronic autoimmune hepatitis. Hepatology Research. 2008;38(8):784–789. doi: 10.1111/j.1872-034X.2008.00347.x.
    1. Floreani A., Niro G., Rosa Rizzotto E., et al. Type I autoimmune hepatitis: Clinical course and outcome in an Italian multicentre study. Alimentary Pharmacology & Therapeutics. 2006;24(7):1051–1057. doi: 10.1111/j.1365-2036.2006.03104.x.
    1. Weiler-Normann C., Lohse A. W. Acute autoimmune hepatitis: many open questions. Journal of Hepatology. 2014;61(4):727–729.
    1. Czaja A. J. Acute and acute severe (Fulminant) autoimmune hepatitis. Digestive Diseases and Sciences. 2013;58(4):897–914. doi: 10.1007/s10620-012-2445-4.
    1. Yeoman A. D., Westbrook R. H., Zen Y., et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome. Journal of Hepatology. 2014;61(4):876–882. doi: 10.1016/j.jhep.2014.06.030. doi: 10.1016/j.jhep.2014.05.021.
    1. Amontree J. S., Stuart T. D., Bredfeldt J. E. Autoimmune chronic active hepatitis masquerading as acute hepatitis. Journal of Clinical Gastroenterology. 1989;11(3):303–307. doi: 10.1097/00004836-198906000-00012.
    1. Czaja A. J., Carpenter H. A. Autoimmune hepatitis with incidental histologic features of bile duct injury. Hepatology. 2001;34(4 I):659–665. doi: 10.1053/jhep.2001.27562.
    1. Leung P. S. C., Rossaro L., Davis P. A., et al. Antimitochondrial antibodies in acute liver failure: Implications for primary biliary cirrhosis. Hepatology. 2007;46(5):1436–1442. doi: 10.1002/hep.21828.
    1. Fujiwara K., Fukuda Y., Yokosuka O. Precise histological evaluation of liver biopsy specimen is indispensable for diagnosis and treatment of acute-onset autoimmune hepatitis. Journal of Gastroenterology. 2008;43(12):951–958. doi: 10.1007/s00535-008-2254-x.
    1. Canh H. N., Harada K., Ouchi H., et al. Acute presentation of autoimmune hepatitis: A multicentre study with detailed histological evaluation in a large cohort of patients. Journal of Clinical Pathology. 2017 doi: 10.1136/jclinpath-2016-204271.
    1. Okano N., Yamamoto K., Sakaguchi K., et al. Clinicopathological features of acute-onset autoimmune hepatitis. Hepatology Research. 2003;25(3):263–270. doi: 10.1016/S1386-6346(02)00274-7.

Source: PubMed

Подписаться